お知らせ • Nov 06
ECMOHO Limited Provides Earnings Guidance for the Third Quarter of 2022 ECMOHO Limited provided earnings guidance for the third quarter of 2022. For the quarter, The company expects that the net loss will decrease in the third quarter of 2022, compared with the same quarter of last year. お知らせ • Oct 27
Nasdaq Stock Market to Delist the American Depositary Shares of Ecmoho Limited On October 26, 2022, Nasdaq Stock Market announced that it will delist the American Depositary Shares of ECMOHO Limited. ECMOHO Limited’s securities were suspended on September 23, 2022, and have not traded on Nasdaq since that time. Nasdaq will file a Form 25 with the Securities and Exchange Commission to complete the delisting. The delisting become effective ten days after the Form 25 is filed. Board Change • Jul 29
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Fang Yuan was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Board Change • Apr 27
Less than half of directors are independent Following the recent departure of a director, there are only 2 independent directors on the board. The company's board is composed of: 2 independent directors. 3 non-independent directors. Independent Director Fang Yuan was the last independent director to join the board, commencing their role in 2021. The company's minority of independent directors is a risk according to the Simply Wall St Risk Model. Buying Opportunity • Feb 26
Now 97% undervalued after recent price drop Over the last 90 days, the stock is down 100%. The fair value is estimated to be US$0.016, however this is not to be taken as a buy recommendation but rather should be used as a guide only. Revenue has been flat over the last 3 years. Earnings per share has grown by 33% per annum over the last 3 years. Reported Earnings • Dec 01
Third quarter 2021 earnings: Revenues in line with analyst expectations Third quarter 2021 results: Revenue: US$28.3m (down 61% from 3Q 2020). Net loss: US$3.75m (loss narrowed 9.0% from 3Q 2020). Revenue was in line with analyst estimates. お知らせ • Sep 23
ECMOHO Limited Announces Receipt of Minimum Bid Price Notice from Nasdaq ECMOHO Limited announced that it received a notification letter dated September 16, 2021 (the “Deficiency Letter”) from the Listing Qualifications Department of The Nasdaq Stock Market Inc. (the “Nasdaq”), indicating that the Company is no longer in compliance with the minimum bid price requirement set forth in Rule 5450(a)(1) of the Nasdaq Listing Rules as the Company’s closing bid price per American depositary share (“ADS”), each representing four Class A ordinary shares, par value $0.00001 per share, of the Company, has been below $1.00 for a period of 30 consecutive business days. The Nasdaq notification letter does not result in the immediate delisting of the Company's securities. Pursuant to Rule 5810(c)(3)(A) of the Nasdaq Listing Rules, the Company has a compliance period of 180 calendar days, or until March 15, 2022 (the “Compliance Period”), to regain compliance with Nasdaq's minimum bid price requirement. If at any time during the Compliance Period, the closing bid price per ADS is at least $1.00 for a minimum of 10 consecutive business days, Nasdaq will provide the Company a written confirmation of compliance and the matter will be closed. In the event that the Company does not regain compliance by March 15, 2022, subject to the determination by the staff of Nasdaq, it may be eligible for an additional 180 calendar days compliance period if it meets the continued listing requirements for market value of publicly held shares and all other initial listing standards, with the exception of bid price requirement, of the Nasdaq Capital Market, and provides written notice to Nasdaq of its intention to cure the deficiency. お知らせ • Sep 02
ECMOHO Limited Provides Preliminary Earnings Guidance for the Third Quarter of 2021 ECMOHO Limited provided preliminary earnings guidance for the third quarter of 2021. For the quarter, the company expects net loss to be significantly decrease. Reported Earnings • Sep 01
Second quarter 2021 earnings released The company reported a soft second quarter result with weaker revenues and control over costs, although losses reduced. Second quarter 2021 results: Revenue: CN¥42.8m (down 94% from 2Q 2020). Net loss: CN¥3.56m (loss narrowed 89% from 2Q 2020). お知らせ • Aug 05
ECMOHO Limited has completed a Follow-on Equity Offering in the amount of $9 million. ECMOHO Limited has completed a Follow-on Equity Offering in the amount of $9 million.
Security Name: American Depositary Shares
Security Type: Depositary Receipt (Common Stock)
Securities Offered: 10,000,000
Price\Range: $0.9
Discount Per Security: $0.063 Reported Earnings • Jun 05
First quarter 2021 earnings released The company reported a poor first quarter result with increased losses, weaker revenues and weaker control over costs. First quarter 2021 results: Revenue: US$27.1m (down 56% from 1Q 2020). Net loss: US$6.07m (loss widened 38% from 1Q 2020). お知らせ • May 18
Ecmoho Limited and Harbin Pharmaceutical Group Announce Joint Launch of New Iron Supplement Product ECMOHO Limited announced that on May 10, 2021, a new product, Puxue Oral Liquid, which is a supplement intended for use by children aged between one and 17, adults, pregnant women, and nursing mothers who suffer from iron and vitamin B12 deficiencies, is jointly launched by the Company and Harbin Pharmaceutical Group Co. Ltd. (“HPGC”). ECMOHO is primarily responsible for the packaging design and sales distribution of the new product. Reported Earnings • May 03
Full year 2020 earnings released The company reported a poor full year result with weaker earnings, revenues and control over costs. Full year 2020 results: Revenue: US$304.9m (down 7.4% from FY 2019). Net loss: US$13.3m (down US$14.3m from profit in FY 2019).